Screener
Celldex Therapeutics CLDX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Net loss | $(152,188) | $(110,396) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,756 | 1,740 |
| Amortization and premium of marketable securities, net | (2,328) | (3,955) |
| Loss on sale or disposal of assets | 4 | 6 |
| Stock-based compensation expense | 16,931 | 18,507 |
| Changes in operating assets and liabilities: | ||
| Accounts and other receivables | 1,785 | 610 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Celldex Therapeutics (CLDX) reported accretion (amortization) of discounts and premiums, investments of $1.7M in Q2 2026.
- How has Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments increased by 0.6% year-over-year, from $1.69M to $1.7M.
- What is the long-term trend for Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 19.8% compound annual growth rate (CAGR), from $3.41M to $5.86M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric represents the non-cash adjustments to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts. It reflects the systematic recognition of interest income over the life of debt instruments held by the company. Investors use this to reconcile net income with actual cash flows generated from investment portfolios.
Ask your AI about Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude